David W. Carley

Chief Tech/Sci/R&D Officer presso Pier Pharmaceuticals, Inc.

Health Technology

Consumer Services

Finance

Profilo

David W.
Carley is currently the Director & Chief Scientific Officer at Pier Pharmaceuticals, Inc. and a Professor at the University of Illinois.
He was formerly a Director at RespireRx Pharmaceuticals, Inc. Carley received a doctorate degree from Harvard University in 1985, a doctorate degree from Massachusetts Institute of Technology, and a graduate degree from Massachusetts Institute of Technology in 1982.

Posizioni attive di David W. Carley

Società	Posizione	Inizio
Pier Pharmaceuticals, Inc. Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO.	Chief Tech/Sci/R&D Officer	29/06/2011
University of Illinois	Corporate Officer/Principal	29/06/2011

Tutte le posizioni attive di David W. Carley

Precedenti posizioni note di David W. Carley

Società	Posizione	Fine
RESPIRERX PHARMACEUTICALS INC.	Director/Board Member	-

Vedi nel dettaglio l'esperienza di David W. Carley

Formazione di David W. Carley

Harvard University	Doctorate Degree
Massachusetts Institute of Technology	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di David W. Carley

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
RESPIRERX PHARMACEUTICALS INC.	Health Technology

Aziende private	1
Pier Pharmaceuticals, Inc. Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO.	Health Technology